Literature DB >> 15906169

PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

Dong Hee Na1, Kang Choon Lee, Patrick P DeLuca.   

Abstract

PURPOSE: : To determine the optimal polyethylene glycol (PEG)-conjugate of octreotide by evaluating the effects of PEGylation chemistry on the biological activity and pharmacokinetic properties.
METHODS: : Octreotide was chemically modified by reaction with succinimidyl propionate monomethoxy PEG (SPA-mPEG, molecular weight 2000) or succinimidyl butyraldehyde-mPEG (ALD-mPEG, molecular weight 2000 and 5000). The structural conformation of PEG-octreotides was evaluated by circular dichroism (CD), the biological activity was assessed by measuring the decrease of serum insulin-like growth factor-I levels in rats, and a pharmacokinetic study was performed after subcutaneous administration in rats. The stability against acylation was investigated with poly(D,L -lactide-co-glycolide) (PLGA).
RESULTS: : ALD-mPEG was site-specific in PEGylating octreotide at the N-terminus. The mono-PEG-octreotides prepared with ALD-mPEG (mono-ALDPEG-octreotide), which alkyl bond preserves the amine's positive charge, showed complete preservation of biological activity, whereas the PEG-octreotides prepared with SPA-mPEG showed lower activity. In the CD analysis, the spectra of the mono-ALDPEG-octreotides were nearly superimposable with that of native octreotide. The mono-ALDPEG-5K-octreotide showed significantly improved pharmacokinetic properties compared with mono-ALDPEG-2K-octreotide as well as native octreotide. Both mono-ALDPEG-2K- and mono-ALDPEG-5K-octreotides were stable against acylation by degrading PLGA.
CONCLUSIONS: : The mono-PEGylation of octreotide at N-terminus with ALD-mPEG produced a conjugate that is biologically and structurally active and stable against acylation by PLGA, and therefore it may serve as a candidate for somatostatin microsphere formulations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906169     DOI: 10.1007/s11095-005-2590-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

Review 1.  Protein instability in poly(lactic-co-glycolic acid) microparticles.

Authors:  M van de Weert; W E Hennink; W Jiskoot
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry.

Authors:  Dong Hee Na; Yu Seok Youn; Sang Deuk Lee; Mi-Won Son; Won-Bae Kim; Patrick P DeLuca; Kang Choon Lee
Journal:  J Control Release       Date:  2003-10-30       Impact factor: 9.776

3.  Optimization of the PEGylation process of a peptide by monitoring with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Dong Hee Na; Yu Seok Youn; Kang Choon Lee
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

4.  Peptide acylation by poly(alpha-hydroxy esters).

Authors:  Andrea Lucke; Josef Kiermaier; Achim Göpferich
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

5.  Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.

Authors:  S J Hunter; J A Shaw; K O Lee; P J Wood; A B Atkinson; J S Bevan
Journal:  Clin Endocrinol (Oxf)       Date:  1999-02       Impact factor: 3.478

Review 6.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

7.  Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

Authors:  M J Knauf; D P Bell; P Hirtzer; Z P Luo; J D Young; N V Katre
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

Review 8.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

9.  Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres.

Authors:  K Fu; D W Pack; A M Klibanov; R Langer
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

10.  Structure of octreotide, a somatostatin analogue.

Authors:  E Pohl; A Heine; G M Sheldrick; Z Dauter; K S Wilson; J Kallen; W Huber; P J Pfäffli
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1995-01-01
View more
  18 in total

1.  Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems.

Authors:  Jae Hwa Ahn; Eun Ji Park; Hye Suk Lee; Kang Choon Lee; Dong Hee Na
Journal:  AAPS PharmSciTech       Date:  2011-09-21       Impact factor: 3.246

2.  The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides.

Authors:  Andreas M Sophocleous; Kashappa-Goud H Desai; J Maxwell Mazzara; Ling Tong; Ji-Xin Cheng; Karl F Olsen; Steven P Schwendeman
Journal:  J Control Release       Date:  2013-09-08       Impact factor: 9.776

3.  Effect of excipients on PLGA film degradation and the stability of an incorporated peptide.

Authors:  M L Houchin; S A Neuenswander; E M Topp
Journal:  J Control Release       Date:  2006-12-01       Impact factor: 9.776

4.  Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles.

Authors:  Ravi D Vaishya; Abhirup Mandal; Mitan Gokulgandhi; Sulabh Patel; Ashim K Mitra
Journal:  Int J Pharm       Date:  2015-05-01       Impact factor: 5.875

5.  Proton Oriented-"Smart Depot" for Responsive Release of Ca2+ to Inhibit Peptide Acylation in PLGA Microspheres.

Authors:  Jiwei Liu; Yan Xu; Yonglu Wang; Hao Ren; Zhengjie Meng; Kuntang Liu; Zhe Liu; He Huang; Xueming Li
Journal:  Pharm Res       Date:  2019-06-04       Impact factor: 4.200

Review 6.  Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

Authors:  Heidi M Mansour; Minji Sohn; Abeer Al-Ghananeem; Patrick P Deluca
Journal:  Int J Mol Sci       Date:  2010-09-15       Impact factor: 5.923

7.  PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.

Authors:  Ryan G Soderquist; Erin D Milligan; Evan M Sloane; Jacqueline A Harrison; Klarika K Douvas; Joseph M Potter; Travis S Hughes; Raymond A Chavez; Kirk Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2009-12       Impact factor: 4.396

8.  PEGylation of interleukin-10 for the mitigation of enhanced pain states.

Authors:  Ryan G Soderquist; Erin D Milligan; Jacqueline A Harrison; Raymond A Chavez; Kirk W Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2010-06-01       Impact factor: 4.396

9.  The use of N-terminal immobilization of PTH(1-34) on PLGA to enhance bioactivity.

Authors:  Jessica L Sharon; David A Puleo
Journal:  Biomaterials       Date:  2008-04-29       Impact factor: 12.479

10.  Enantioselective synthesis of (2R, 3S)- and (2S, 3R)-4,4,4-trifluoro-N-Fmoc-O-tert-butyl-threonine and their racemization-free incorporation into oligopeptides via solid-phase synthesis.

Authors:  Nu Xiao; Zhong-Xing Jiang; Y Bruce Yu
Journal:  Biopolymers       Date:  2007       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.